

Global Monoclonal Antibody Drugs for Cancer Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/GA37DD824ABEEN.html>

Date: September 2026

Pages: 132

Price: US\$ 3,660.00 (Single User License)

ID: GA37DD824ABEEN

Abstracts

The global Monoclonal Antibody Drugs for Cancer market size is predicted to grow from US\$ 108690 million in 2025 to US\$ 194270 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.

LPI (LP Information)' newest research report, the “Monoclonal Antibody Drugs for Cancer Industry Forecast” looks at past sales and reviews total world Monoclonal Antibody Drugs for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibody Drugs for Cancer sales for 2026 through 2032. With Monoclonal Antibody Drugs for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Monoclonal Antibody Drugs for Cancer industry.

This Insight Report provides a comprehensive analysis of the global Monoclonal Antibody Drugs for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Monoclonal Antibody Drugs for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Monoclonal Antibody Drugs for Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibody Drugs for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibody Drugs for Cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibody Drugs for Cancer market by product type, application, key players and key regions and countries.

Segmentation by Type:

Mouse-derived Antibodies

Chimeric Antibodies

Humanized Antibodies

Segmentation by Application:

Lung Cancer

Breast Cancer

Prostate Cancer

Blood-related Cancer

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol-Myers Squibb

Amgen

AstraZeneca

Merck & Co

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer

Regeneron

Innovent

Hengrui Medicine

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Monoclonal Antibody Drugs for Cancer Market Size (2021-2032)
 - 2.1.2 Monoclonal Antibody Drugs for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Monoclonal Antibody Drugs for Cancer by Country/Region (2021, 2025 & 2032)
- 2.2 Monoclonal Antibody Drugs for Cancer Segment by Type
 - 2.2.1 Mouse-derived Antibodies
 - 2.2.2 Chimeric Antibodies
 - 2.2.3 Humanized Antibodies
 - 2.2.4 Monoclonal Antibody Drugs for Cancer Market Size by Type
 - 2.2.4.1 Monoclonal Antibody Drugs for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.4.2 Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2021-2026)
- 2.3 Monoclonal Antibody Drugs for Cancer Segment by Application
 - 2.3.1 Lung Cancer
 - 2.3.2 Breast Cancer
 - 2.3.3 Prostate Cancer
 - 2.3.4 Blood-related Cancer
 - 2.3.5 Other
 - 2.3.6 Monoclonal Antibody Drugs for Cancer Market Size by Application
 - 2.3.6.1 Monoclonal Antibody Drugs for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.3.6.2 Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application (2021-2026)

3 MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET SIZE BY PLAYER

3.1 Monoclonal Antibody Drugs for Cancer Market Size Market Share by Player

3.1.1 Global Monoclonal Antibody Drugs for Cancer Revenue by Player (2021-2026)

3.1.2 Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Player (2021-2026)

3.2 Global Monoclonal Antibody Drugs for Cancer Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 MONOCLONAL ANTIBODY DRUGS FOR CANCER BY REGION

4.1 Monoclonal Antibody Drugs for Cancer Market Size by Region (2021-2026)

4.2 Global Monoclonal Antibody Drugs for Cancer Annual Revenue by Country/Region (2021-2026)

4.3 Americas Monoclonal Antibody Drugs for Cancer Market Size Growth (2021-2026)

4.4 APAC Monoclonal Antibody Drugs for Cancer Market Size Growth (2021-2026)

4.5 Europe Monoclonal Antibody Drugs for Cancer Market Size Growth (2021-2026)

4.6 Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Monoclonal Antibody Drugs for Cancer Market Size by Country (2021-2026)

5.2 Americas Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026)

5.3 Americas Monoclonal Antibody Drugs for Cancer Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Monoclonal Antibody Drugs for Cancer Market Size by Region (2021-2026)

6.2 APAC Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026)

6.3 APAC Monoclonal Antibody Drugs for Cancer Market Size by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Monoclonal Antibody Drugs for Cancer Market Size by Country
(2021-2026)

7.2 Europe Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026)

7.3 Europe Monoclonal Antibody Drugs for Cancer Market Size by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Monoclonal Antibody Drugs for Cancer by Region
(2021-2026)

8.2 Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Type
(2021-2026)

8.3 Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by
Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL MONOCLONAL ANTIBODY DRUGS FOR CANCER MARKET FORECAST

10.1 Global Monoclonal Antibody Drugs for Cancer Forecast by Region (2027-2032)

10.1.1 Global Monoclonal Antibody Drugs for Cancer Forecast by Region (2027-2032)

10.1.2 Americas Monoclonal Antibody Drugs for Cancer Forecast

10.1.3 APAC Monoclonal Antibody Drugs for Cancer Forecast

10.1.4 Europe Monoclonal Antibody Drugs for Cancer Forecast

10.1.5 Middle East & Africa Monoclonal Antibody Drugs for Cancer Forecast

10.2 Americas Monoclonal Antibody Drugs for Cancer Forecast by Country (2027-2032)

10.2.1 United States Market Monoclonal Antibody Drugs for Cancer Forecast

10.2.2 Canada Market Monoclonal Antibody Drugs for Cancer Forecast

10.2.3 Mexico Market Monoclonal Antibody Drugs for Cancer Forecast

10.2.4 Brazil Market Monoclonal Antibody Drugs for Cancer Forecast

10.3 APAC Monoclonal Antibody Drugs for Cancer Forecast by Region (2027-2032)

10.3.1 China Monoclonal Antibody Drugs for Cancer Market Forecast

10.3.2 Japan Market Monoclonal Antibody Drugs for Cancer Forecast

10.3.3 Korea Market Monoclonal Antibody Drugs for Cancer Forecast

10.3.4 Southeast Asia Market Monoclonal Antibody Drugs for Cancer Forecast

10.3.5 India Market Monoclonal Antibody Drugs for Cancer Forecast

10.3.6 Australia Market Monoclonal Antibody Drugs for Cancer Forecast

10.4 Europe Monoclonal Antibody Drugs for Cancer Forecast by Country (2027-2032)

10.4.1 Germany Market Monoclonal Antibody Drugs for Cancer Forecast

10.4.2 France Market Monoclonal Antibody Drugs for Cancer Forecast

10.4.3 UK Market Monoclonal Antibody Drugs for Cancer Forecast

10.4.4 Italy Market Monoclonal Antibody Drugs for Cancer Forecast

10.4.5 Russia Market Monoclonal Antibody Drugs for Cancer Forecast

10.5 Middle East & Africa Monoclonal Antibody Drugs for Cancer Forecast by Region (2027-2032)

10.5.1 Egypt Market Monoclonal Antibody Drugs for Cancer Forecast

- 10.5.2 South Africa Market Monoclonal Antibody Drugs for Cancer Forecast
- 10.5.3 Israel Market Monoclonal Antibody Drugs for Cancer Forecast
- 10.5.4 Turkey Market Monoclonal Antibody Drugs for Cancer Forecast
- 10.6 Global Monoclonal Antibody Drugs for Cancer Forecast by Type (2027-2032)
- 10.7 Global Monoclonal Antibody Drugs for Cancer Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Monoclonal Antibody Drugs for Cancer Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 Johnson & Johnson
 - 11.1.1 Johnson & Johnson Company Information
 - 11.1.2 Johnson & Johnson Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.1.3 Johnson & Johnson Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.1.4 Johnson & Johnson Main Business Overview
 - 11.1.5 Johnson & Johnson Latest Developments
- 11.2 Novartis
 - 11.2.1 Novartis Company Information
 - 11.2.2 Novartis Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.2.3 Novartis Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.2.4 Novartis Main Business Overview
 - 11.2.5 Novartis Latest Developments
- 11.3 Gilead Sciences
 - 11.3.1 Gilead Sciences Company Information
 - 11.3.2 Gilead Sciences Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.3.3 Gilead Sciences Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.3.4 Gilead Sciences Main Business Overview
 - 11.3.5 Gilead Sciences Latest Developments
- 11.4 Roche
 - 11.4.1 Roche Company Information
 - 11.4.2 Roche Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.4.3 Roche Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.4.4 Roche Main Business Overview
 - 11.4.5 Roche Latest Developments
- 11.5 Bristol-Myers Squibb

- 11.5.1 Bristol-Myers Squibb Company Information
- 11.5.2 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product Offered
- 11.5.3 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
- 11.5.4 Bristol-Myers Squibb Main Business Overview
- 11.5.5 Bristol-Myers Squibb Latest Developments
- 11.6 Amgen
 - 11.6.1 Amgen Company Information
 - 11.6.2 Amgen Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.6.3 Amgen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Amgen Main Business Overview
 - 11.6.5 Amgen Latest Developments
- 11.7 AstraZeneca
 - 11.7.1 AstraZeneca Company Information
 - 11.7.2 AstraZeneca Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.7.3 AstraZeneca Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 AstraZeneca Main Business Overview
 - 11.7.5 AstraZeneca Latest Developments
- 11.8 Merck & Co
 - 11.8.1 Merck & Co Company Information
 - 11.8.2 Merck & Co Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.8.3 Merck & Co Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Merck & Co Main Business Overview
 - 11.8.5 Merck & Co Latest Developments
- 11.9 Takeda
 - 11.9.1 Takeda Company Information
 - 11.9.2 Takeda Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.9.3 Takeda Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Takeda Main Business Overview
 - 11.9.5 Takeda Latest Developments
- 11.10 Merck KGaA
 - 11.10.1 Merck KGaA Company Information
 - 11.10.2 Merck KGaA Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.10.3 Merck KGaA Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)

- 11.10.4 Merck KGaA Main Business Overview
- 11.10.5 Merck KGaA Latest Developments
- 11.11 Seagen
 - 11.11.1 Seagen Company Information
 - 11.11.2 Seagen Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.11.3 Seagen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 Seagen Main Business Overview
 - 11.11.5 Seagen Latest Developments
- 11.12 Eli Lilly
 - 11.12.1 Eli Lilly Company Information
 - 11.12.2 Eli Lilly Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.12.3 Eli Lilly Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 Eli Lilly Main Business Overview
 - 11.12.5 Eli Lilly Latest Developments
- 11.13 Ono Pharmaceutical
 - 11.13.1 Ono Pharmaceutical Company Information
 - 11.13.2 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.13.3 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 Ono Pharmaceutical Main Business Overview
 - 11.13.5 Ono Pharmaceutical Latest Developments
- 11.14 Pfizer
 - 11.14.1 Pfizer Company Information
 - 11.14.2 Pfizer Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.14.3 Pfizer Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.14.4 Pfizer Main Business Overview
 - 11.14.5 Pfizer Latest Developments
- 11.15 Regeneron
 - 11.15.1 Regeneron Company Information
 - 11.15.2 Regeneron Monoclonal Antibody Drugs for Cancer Product Offered
 - 11.15.3 Regeneron Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)
 - 11.15.4 Regeneron Main Business Overview
 - 11.15.5 Regeneron Latest Developments
- 11.16 Innovent
 - 11.16.1 Innovent Company Information

11.16.2 Innovent Monoclonal Antibody Drugs for Cancer Product Offered

11.16.3 Innovent Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)

11.16.4 Innovent Main Business Overview

11.16.5 Innovent Latest Developments

11.17 Hengrui Medicine

11.17.1 Hengrui Medicine Company Information

11.17.2 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product Offered

11.17.3 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2021-2026)

11.17.4 Hengrui Medicine Main Business Overview

11.17.5 Hengrui Medicine Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Monoclonal Antibody Drugs for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Monoclonal Antibody Drugs for Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Mouse-derived Antibodies

Table 4. Major Players of Chimeric Antibodies

Table 5. Major Players of Humanized Antibodies

Table 6. Monoclonal Antibody Drugs for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 7. Global Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026) & (\$ millions)

Table 8. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2021-2026)

Table 9. Monoclonal Antibody Drugs for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 10. Global Monoclonal Antibody Drugs for Cancer Market Size by Application (2021-2026) & (\$ millions)

Table 11. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application (2021-2026)

Table 12. Global Monoclonal Antibody Drugs for Cancer Revenue by Player (2021-2026) & (\$ millions)

Table 13. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Player (2021-2026)

Table 14. Monoclonal Antibody Drugs for Cancer Key Players Head office and Products Offered

Table 15. Monoclonal Antibody Drugs for Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 16. New Products and Potential Entrants

Table 17. Mergers & Acquisitions, Expansion

Table 18. Global Monoclonal Antibody Drugs for Cancer Market Size by Region (2021-2026) & (\$ millions)

Table 19. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Region (2021-2026)

Table 20. Global Monoclonal Antibody Drugs for Cancer Revenue by Country/Region (2021-2026) & (\$ millions)

Table 21. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Country/Region (2021-2026)

Table 22. Americas Monoclonal Antibody Drugs for Cancer Market Size by Country (2021-2026) & (\$ millions)

Table 23. Americas Monoclonal Antibody Drugs for Cancer Market Size Market Share by Country (2021-2026)

Table 24. Americas Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026) & (\$ millions)

Table 25. Americas Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2021-2026)

Table 26. Americas Monoclonal Antibody Drugs for Cancer Market Size by Application (2021-2026) & (\$ millions)

Table 27. Americas Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application (2021-2026)

Table 28. APAC Monoclonal Antibody Drugs for Cancer Market Size by Region (2021-2026) & (\$ millions)

Table 29. APAC Monoclonal Antibody Drugs for Cancer Market Size Market Share by Region (2021-2026)

Table 30. APAC Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026) & (\$ millions)

Table 31. APAC Monoclonal Antibody Drugs for Cancer Market Size by Application (2021-2026) & (\$ millions)

Table 32. Europe Monoclonal Antibody Drugs for Cancer Market Size by Country (2021-2026) & (\$ millions)

Table 33. Europe Monoclonal Antibody Drugs for Cancer Market Size Market Share by Country (2021-2026)

Table 34. Europe Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026) & (\$ millions)

Table 35. Europe Monoclonal Antibody Drugs for Cancer Market Size by Application (2021-2026) & (\$ millions)

Table 36. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Region (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Type (2021-2026) & (\$ millions)

Table 38. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size by Application (2021-2026) & (\$ millions)

Table 39. Key Market Drivers & Growth Opportunities of Monoclonal Antibody Drugs for Cancer

Table 40. Key Market Challenges & Risks of Monoclonal Antibody Drugs for Cancer

Table 41. Key Industry Trends of Monoclonal Antibody Drugs for Cancer
Table 42. Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Region (2027-2032) & (\$ millions)
Table 43. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Type (2027-2032) & (\$ millions)
Table 45. Global Monoclonal Antibody Drugs for Cancer Market Size Forecast by Application (2027-2032) & (\$ millions)
Table 46. Johnson & Johnson Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 47. Johnson & Johnson Monoclonal Antibody Drugs for Cancer Product Offered
Table 48. Johnson & Johnson Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 49. Johnson & Johnson Main Business
Table 50. Johnson & Johnson Latest Developments
Table 51. Novartis Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 52. Novartis Monoclonal Antibody Drugs for Cancer Product Offered
Table 53. Novartis Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 54. Novartis Main Business
Table 55. Novartis Latest Developments
Table 56. Gilead Sciences Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 57. Gilead Sciences Monoclonal Antibody Drugs for Cancer Product Offered
Table 58. Gilead Sciences Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 59. Gilead Sciences Main Business
Table 60. Gilead Sciences Latest Developments
Table 61. Roche Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 62. Roche Monoclonal Antibody Drugs for Cancer Product Offered
Table 63. Roche Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 64. Roche Main Business
Table 65. Roche Latest Developments
Table 66. Bristol-Myers Squibb Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors

Table 67. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product Offered

Table 68. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 69. Bristol-Myers Squibb Main Business

Table 70. Bristol-Myers Squibb Latest Developments

Table 71. Amgen Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors

Table 72. Amgen Monoclonal Antibody Drugs for Cancer Product Offered

Table 73. Amgen Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 74. Amgen Main Business

Table 75. Amgen Latest Developments

Table 76. AstraZeneca Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors

Table 77. AstraZeneca Monoclonal Antibody Drugs for Cancer Product Offered

Table 78. AstraZeneca Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 79. AstraZeneca Main Business

Table 80. AstraZeneca Latest Developments

Table 81. Merck & Co Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors

Table 82. Merck & Co Monoclonal Antibody Drugs for Cancer Product Offered

Table 83. Merck & Co Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 84. Merck & Co Main Business

Table 85. Merck & Co Latest Developments

Table 86. Takeda Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors

Table 87. Takeda Monoclonal Antibody Drugs for Cancer Product Offered

Table 88. Takeda Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 89. Takeda Main Business

Table 90. Takeda Latest Developments

Table 91. Merck KGaA Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors

Table 92. Merck KGaA Monoclonal Antibody Drugs for Cancer Product Offered

Table 93. Merck KGaA Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 94. Merck KGaA Main Business

Table 95. Merck KGaA Latest Developments
Table 96. Seagen Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 97. Seagen Monoclonal Antibody Drugs for Cancer Product Offered
Table 98. Seagen Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 99. Seagen Main Business
Table 100. Seagen Latest Developments
Table 101. Eli Lilly Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 102. Eli Lilly Monoclonal Antibody Drugs for Cancer Product Offered
Table 103. Eli Lilly Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 104. Eli Lilly Main Business
Table 105. Eli Lilly Latest Developments
Table 106. Ono Pharmaceutical Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 107. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product Offered
Table 108. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 109. Ono Pharmaceutical Main Business
Table 110. Ono Pharmaceutical Latest Developments
Table 111. Pfizer Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 112. Pfizer Monoclonal Antibody Drugs for Cancer Product Offered
Table 113. Pfizer Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 114. Pfizer Main Business
Table 115. Pfizer Latest Developments
Table 116. Regeneron Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 117. Regeneron Monoclonal Antibody Drugs for Cancer Product Offered
Table 118. Regeneron Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 119. Regeneron Main Business
Table 120. Regeneron Latest Developments
Table 121. Innovent Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors
Table 122. Innovent Monoclonal Antibody Drugs for Cancer Product Offered

Table 123. Innovent Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 124. Innovent Main Business

Table 125. Innovent Latest Developments

Table 126. Hengrui Medicine Details, Company Type, Monoclonal Antibody Drugs for Cancer Area Served and Its Competitors

Table 127. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product Offered

Table 128. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 129. Hengrui Medicine Main Business

Table 130. Hengrui Medicine Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Monoclonal Antibody Drugs for Cancer Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Monoclonal Antibody Drugs for Cancer Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Monoclonal Antibody Drugs for Cancer Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Monoclonal Antibody Drugs for Cancer Sales Market Share by Country/Region (2025)

Figure 8. Monoclonal Antibody Drugs for Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type in 2025

Figure 10. Monoclonal Antibody Drugs for Cancer in Lung Cancer

Figure 11. Global Monoclonal Antibody Drugs for Cancer Market: Lung Cancer (2021-2026) & (\$ millions)

Figure 12. Monoclonal Antibody Drugs for Cancer in Breast Cancer

Figure 13. Global Monoclonal Antibody Drugs for Cancer Market: Breast Cancer (2021-2026) & (\$ millions)

Figure 14. Monoclonal Antibody Drugs for Cancer in Prostate Cancer

Figure 15. Global Monoclonal Antibody Drugs for Cancer Market: Prostate Cancer (2021-2026) & (\$ millions)

Figure 16. Monoclonal Antibody Drugs for Cancer in Blood-related Cancer

Figure 17. Global Monoclonal Antibody Drugs for Cancer Market: Blood-related Cancer (2021-2026) & (\$ millions)

Figure 18. Monoclonal Antibody Drugs for Cancer in Other

Figure 19. Global Monoclonal Antibody Drugs for Cancer Market: Other (2021-2026) & (\$ millions)

Figure 20. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application in 2025

Figure 21. Global Monoclonal Antibody Drugs for Cancer Revenue Market Share by Player in 2025

Figure 22. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share by Region (2021-2026)

Figure 23. Americas Monoclonal Antibody Drugs for Cancer Market Size 2021-2026 (\$ millions)

Figure 24. APAC Monoclonal Antibody Drugs for Cancer Market Size 2021-2026 (\$ millions)

Figure 25. Europe Monoclonal Antibody Drugs for Cancer Market Size 2021-2026 (\$ millions)

Figure 26. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size 2021-2026 (\$ millions)

Figure 27. Americas Monoclonal Antibody Drugs for Cancer Value Market Share by Country in 2025

Figure 28. United States Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 29. Canada Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 30. Mexico Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 31. Brazil Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 32. APAC Monoclonal Antibody Drugs for Cancer Market Size Market Share by Region in 2025

Figure 33. APAC Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2021-2026)

Figure 34. APAC Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application (2021-2026)

Figure 35. China Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 36. Japan Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 37. South Korea Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 38. Southeast Asia Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 39. India Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 40. Australia Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 41. Europe Monoclonal Antibody Drugs for Cancer Market Size Market Share by Country in 2025

Figure 42. Europe Monoclonal Antibody Drugs for Cancer Market Size Market Share by

Type (2021-2026)

Figure 43. Europe Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application (2021-2026)

Figure 44. Germany Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 45. France Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 46. UK Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 47. Italy Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 48. Russia Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 49. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size Market Share by Region (2021-2026)

Figure 50. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2021-2026)

Figure 51. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application (2021-2026)

Figure 52. Egypt Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 53. South Africa Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 54. Israel Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 55. Turkey Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 56. GCC Countries Monoclonal Antibody Drugs for Cancer Market Size Growth 2021-2026 (\$ millions)

Figure 57. Americas Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 58. APAC Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 59. Europe Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 60. Middle East & Africa Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 61. United States Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 62. Canada Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 63. Mexico Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 64. Brazil Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 65. China Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 66. Japan Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 67. Korea Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 68. Southeast Asia Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 69. India Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 70. Australia Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 71. Germany Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 72. France Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 73. UK Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 74. Italy Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 75. Russia Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 76. Egypt Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 77. South Africa Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 78. Israel Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 79. Turkey Monoclonal Antibody Drugs for Cancer Market Size 2027-2032 (\$ millions)

Figure 80. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share Forecast by Type (2027-2032)

Figure 81. Global Monoclonal Antibody Drugs for Cancer Market Size Market Share

Forecast by Application (2027-2032)

Figure 82. GCC Countries Monoclonal Antibody Drugs for Cancer Market Size
2027-2032 (\$ millions)

I would like to order

Product name: Global Monoclonal Antibody Drugs for Cancer Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/GA37DD824ABEEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA37DD824ABEEN.html>